Concurrent radiochemotherapy in the treatment of locally advanced non-small cell lung cancer

Branislav Jeremic, Mitchell Machtay

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Current evidence suggests that concurrent RT/CHT is the standard of treatment in patients with locally advanced, inoperable NSCLC. This treatment approach, however, bears risk of increased toxicity and, therefore, must be carefully balanced regarding the choice of patients suitable for such an intervention. Newer RT technologies, third-generation CHT drugs, and widely used radioprotectors represent the current framework for numerous clinical studies that ultimately will help optimize the treatment of this disease.

Original languageEnglish (US)
Pages (from-to)91-100
Number of pages10
JournalHematology/Oncology Clinics of North America
Volume18
Issue number1
DOIs
StatePublished - Feb 2004

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Concurrent radiochemotherapy in the treatment of locally advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this